The ROE as of November 2024 (TTM) for Lineage Cell Therapeutics, Inc. (LCTX) is -29.91%

According to Lineage Cell Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is -29.91%. This represents a change of 303.15% compared to the average of -7.42% of the last 4 quarters.

Lineage Cell Therapeutics, Inc. (LCTX) Historical ROE (quarterly & annually)

How has LCTX ROE performed in the past?

The mean historical ROE of Lineage Cell Therapeutics, Inc. over the last ten years is -45.10%. The current -29.91% ROE has changed -33.68% with respect to the historical average. Over the past ten years (40 quarters), LCTX's ROE was at its highest in in the September 2018 quarter at 38.99%. The ROE was at its lowest in in the March 2016 quarter at -157.69%.

Lineage Cell Therapeutics, Inc. (LCTX) ROE by Quarter and Year

Discovering the peaks and valleys of Lineage Cell Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Lineage Cell Therapeutics, Inc. (LCTX) Average ROE

How has LCTX ROE performed in the past?

The current ROE of Lineage Cell Therapeutics, Inc. (LCTX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Lineage Cell Therapeutics, Inc. (LCTX) ROE vs. Peers

How is LCTX’s ROE compared to its peers?

Lineage Cell Therapeutics, Inc.’s ROE is less than MAIA Biotechnology, Inc. (20.47%), less than Armata Pharmaceuticals, Inc. (89.12%), greater than Frequency Therapeutics, Inc. (-54.56%), greater than Portage Biotech Inc. (-267.72%), less than AgeX Therapeutics, Inc. (172.71%), greater than Cadrenal Therapeutics, Inc. Common Stock (-142.95%), greater than ImmuCell Corporation (-2833.46%), greater than Oxford Nanopore Technologies plc (-43.29%), greater than Replimune Group, Inc. (-53.12%), greater than Nuvectis Pharma, Inc. (-155.80%), greater than Lyra Therapeutics, Inc. (-178.68%), greater than Kronos Bio, Inc. (-64.55%), greater than Gossamer Bio, Inc. (-127.28%), greater than Neoleukin Therapeutics, Inc. (-8.54%), greater than Nuvation Bio Inc. (-108.68%), greater than Ovid Therapeutics Inc. (-39.24%), greater than NextCure, Inc. (-62.50%), less than Connect Biopharma Holdings Limited (7.21%), less than Spero Therapeutics, Inc. (3.36%), greater than Bolt Biotherapeutics, Inc. (-69.46%), less than Coherus BioSciences, Inc. (0.40%), greater than Gracell Biotechnologies Inc. (-15.56%),

Build a custom stock screener for Lineage Cell Therapeutics, Inc. (LCTX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Lineage Cell Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Lineage Cell Therapeutics, Inc. (LCTX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Lineage Cell Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.